无羁萜 | 559-74-0

• 物质功能分类: 天然产物 - 萜类
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 无羁萜
• 中文别名: 木栓酮
• 英文名称: friedelin
• 英文别名: friedelan-3-one；3-oxofriedelane；Friedeline；friedelanone；(4R,4aS,6aS,6aS,6bR,8aR,12aR,14aS,14bS)-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1H-picen-3-one
• CAS: 559-74-0
• 化学式: C₃₀H₅₀O
• mdl: MFCD00017296
• 分子量: 426.726
• InChiKey: OFMXGFHWLZPCFL-SVRPQWSVSA-N

物化性质

• 熔点：
  262-265 °C (lit.)
• 比旋光度：
  D -27.8° (chloroform)
• 沸点：
  477.2±13.0 °C(Predicted)
• 密度：
  0.963±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）
• LogP：
  10.287 (est)

计算性质

• 辛醇/水分配系数(LogP)：
  9.8
• 重原子数：
  31
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.966
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• WGK Germany：
  3
• 储存条件：
  2-8℃

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : Friedelin
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 559-74-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No 1272/2008
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
The product does not need to be labelled in accordance with EC directives or respective national laws.
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Synonyms : Friedelan-3-one
DA-friedooleanan-3-one
Formula : C30H50O
Molecular Weight : 426,72 g/mol
CAS-No. : 559-74-0
EC-No. : 209-205-1
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 262 - 265 °C - lit.
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

性质

无羁萜（Friedelin）是一种典型的三萜类化合物，属于木栓烷型五环三萜。它为白色针状结晶，熔点在263-263.5℃之间，能够溶解于氯仿、石油醚等有机溶剂中，但不溶于水。

存在形式

无羁萜存在于多种植物中，如卫矛科的卫矛全草、大戟科的重阳木茎以及石蕊科的雀儿石蕊枝状体等。

应用

无羁萜具有广泛的生物活性和医疗应用价值，包括抗炎、镇痛、抗氧化、自由基清除以及良好的抑制致病细菌和真菌作用。此外，它还具备杀虫效果，可用于植物保护领域。

制备

以竹茹粗粉为原料（1kg），加入5倍量正己烷，加热回流提取4次，每次2小时，合并提取液后浓缩至浸膏状态。使用70%的乙醇进行洗涤，再用乙酸乙酯萃取。从乙酸乙酯萃取液中，通过浓缩至小体积并加入适量硅胶搅拌均匀的方法，干法上硅胶柱，依次用8∶1、19∶1、24∶1、47∶1的氯仿-甲醇混合溶液洗脱。收集富含无羁萜成分的洗脱液，经脱溶后用乙醇回流溶解并放冷结晶两次，滤出结晶干燥，最终获得木栓酮产品3.1g，纯度为92.7%。

生物活性

Friedelin是从Maytenus ilicifolia(Mart)的叶子中分离得到的一种成分。它作为CYP3A4的非竞争性抑制剂，IC50和Ki值分别为10.79 μM 和6.16 μM；同时，它是CYP2E1的竞争性抑制剂，IC50和Ki值分别为22.54 μM和18.02 μM。

靶点

• IC50: 10.79 μM (CYP3A4), 22.54 μM (CYP2E1)
• Ki: 6.16 μM(CYP3A4), 18.02 μM(CYP2E1)

反应信息

• 作为反应物：
  描述：

  无羁萜 在 silver(I) acetate 、 苯甲酰氯 作用下， 生成 黏黴酮
  参考文献：
  名称：

  The Structures of the Triterpenes Friedelin and Cerin^1,2

  摘要：

  DOI：

  10.1021/ja01600a064
• 作为产物：
  描述：

  4α-bromofriedelin 在 N,N-二甲基苯胺 作用下， 反应 6.0h， 生成 无羁萜
  参考文献：
  名称：

  Ghosh, Pranab; Chakraborty, Prasanta, Journal of the Indian Chemical Society, 2011, vol. 88, # 7, p. 1037 - 1039

  摘要：

  DOI：

文献信息

• [EN] BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY<br/>[FR] CONJUGUÉS BIOACTIFS POUR L'ADMINISTRATION D'OLIGONUCLÉOTIDES
  申请人：UNIV MASSACHUSETTS

  公开号：WO2017030973A1

  公开（公告）日：2017-02-23

  Provided herein are self-delivering oligonucleotides that are characterized by efficient RISC entry, minimum immune response and off-target effects, efficient cellular uptake without formulation, and efficient and specific tissue distribution.

  本文提供的自递送寡核苷酸具有高效的RISC进入、最小的免疫反应和非靶效应、无需配方的高效细胞摄取，以及高效和特异的组织分布。
• CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20160051691A1

  公开（公告）日：2016-02-25

  The present invention provides iRNA agents comprising at least one subunit of the formula (I): wherein: A and B are each independently for each occurrence O, N(R N ) or S; X and Y are each independently for each occurrence H, OH, a hydroxyl protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-Linker-OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, an oligonucleotide, —P(Z′)(Z″)-formula(I), —P(Z′)(Z″)— or -Linker-R; R is L G , -Linker-L G , or has the structure shown below: L G is independently for each occurrence a carbohydrate, e.g., monosaccharide, disaccharide, trisaccharide, tetrasaccharide, oligosaccharide, polysaccharide; R N is independently for each occurrence H, methyl, ethyl, propyl, isopropyl, butyl, or benzyl; and Z′, Z″, Z′″ and Z″″ are each independently for each occurrence O or S.

  本发明提供了包含至少一个式(I)的亚单位的iRNA试剂： 其中： A和B分别独立于每次出现O、N(RN)或S； X和Y分别独立于每次出现H、OH、一个羟基保护基团、一个磷酸基团、一个磷酸二酯基团、一个活化磷酸基团、一个活化亚磷酸基团、一个磷酰胺基团、一个固相支持、-P(Z')(Z″)O-核苷、-P(Z')(Z″)O-寡核苷酸、一个脂质、一个PEG、一个类固醇、一个亲脂物质、一个聚合物、-P(Z')(Z″)O-连接子-OP(Z′″)(Z″″)O-寡核苷酸、一个核苷酸、一个寡核苷酸、-P(Z')(Z″)-式(I)、-P(Z')(Z″)-或-连接子-R； R是LG、-连接子-LG，或具有下面所示结构： LG独立于每次出现的是一种碳水化合物，例如，单糖、双糖、三糖、四糖、寡糖、多糖； RN独立于每次出现的是H、甲基、乙基、丙基、异丙基、丁基或苄基； Z'、Z″、Z′″和Z″″分别独立于每次出现的是O或S。
• Reduction of Steroid Ketones and other Carbonyl Compounds by Modified Wolff--Kishner Method
  作者：[not available]. Huang-Minlon

  DOI：10.1021/ja01178a008

  日期：1949.10

  concentration of the regenerated ketone a t a low level.2 In fact all the C3-steroid ketones so far investigated gave the normal C3-methylenic compounds by the modified Wolff-Kish20-diketopregnane (I) gave a reduced product melting a t 152-153' in which one of the two keto groups is unattacked. In view of the fact that the 20-keto compounds, such as A5-pregnen-3 (P)-ol20-one (IV) and its hydrogenation product

  根据Dutcher 和Wintersteiner2，在通常条件下通过Wow-Kishner 方法还原C3-类固醇酮主要产生相应的Cs-差向异构甲醇和少量预期的Cs-亚甲基产物。在α,P-不饱和酮、胆甾酮的情况下，还原遵循更复杂的过程。除了差向异构不饱和甲醇和少量正常产物A4-胆甾醇外，还分离出饱和甲醇、α-粪甾醇和P-胆甾醇。作者指出，异常还原可以通过以下假设来解释：腙或缩氨基脲部分水解为游离酮，然后被醇钠还原为仲醇。然而，这些可能性被修改后的 WolffKishner red ~ ction 消除，~ , ~ 其中水在加热期间蒸发。此外，该反应中使用过量的水合肼应将再生酮的浓度保持在较低水平。 2 事实上，迄今为止研究的所有 C3-甾体酮都通过改性的 Wolff-Kish20-二酮孕烷得到了正常的 C3-亚甲基化合物(I) 得到在 152-153' 熔化的还原产物，其中两个酮基中的一个未
• [EN] CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS ANTISENS CONJUGUÉS ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2014179620A1

  公开（公告）日：2014-11-06

  Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.

  本文提供了具有共轭基团的寡聚化合物。在某些实施例中，这些寡聚化合物与N-乙酰半乳糖结合。
• [EN] TARGETED THERAPEUTIC NUCLEOSIDES AND THEIR USE<br/>[FR] NUCLÉOSIDES THÉRAPEUTIQUES CIBLÉES ET LEUR UTILISATION
  申请人：ISIS PHARMACEUTICALS INC

  公开号：WO2015042447A1

  公开（公告）日：2015-03-26

  Provided herein are compounds comprising one or more therapeutic nucleosides and one or more targeting groups. In certain embodiments, the compounds further comprise one or more oligonucleotides. In certain embodiments, a targeting group comprises one or more N-Acetylgalactosamine.

  本文提供的化合物包括一个或多个治疗性核苷和一个或多个靶向基团。在某些实施例中，这些化合物进一步包括一个或多个寡核苷酸。在某些实施例中，一个靶向基团包括一个或多个N-乙酰半乳糖胺。

表征谱图